<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03755778</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 938-003</org_study_id>
    <nct_id>NCT03755778</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects</brief_title>
  <official_title>A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Research Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects
      of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in
      Healthy Subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Actual">January 27, 2019</completion_date>
  <primary_completion_date type="Actual">January 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>3-Part Single Group study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of EDP-938 with and without coadministration with itraconazole</measure>
    <time_frame>Up to 19 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of EDP-938 with and without coadministration with itraconazole</measure>
    <time_frame>Up to 19 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of EDP-938 with and without coadministration with rifampin</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of EDP-938 with and without coadministration with rifampin</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of EDP-938 with and without coadministration with quinidine</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of EDP-938 with and without coadministration with quinidine</measure>
    <time_frame>Up to 13 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 25 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>RSV Infection</condition>
  <arm_group>
    <arm_group_label>EDP-938 and itraconazole interaction (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-938 and rifampin interaction (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-938 and quinidine interaction (Part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938</intervention_name>
    <description>Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)</description>
    <arm_group_label>EDP-938 and itraconazole interaction (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938</intervention_name>
    <description>Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)</description>
    <arm_group_label>EDP-938 and rifampin interaction (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938</intervention_name>
    <description>Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)</description>
    <arm_group_label>EDP-938 and quinidine interaction (Part 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Subjects will receive itraconazole once daily from Day 5 to Day 18</description>
    <arm_group_label>EDP-938 and itraconazole interaction (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Subjects will receive rifampin once daily from Day 5 to Day 16</description>
    <arm_group_label>EDP-938 and rifampin interaction (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinidine</intervention_name>
    <description>Subjects will receive quinidine once daily from Day 5 to Day 12</description>
    <arm_group_label>EDP-938 and quinidine interaction (Part 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An informed consent document signed and dated by the subject.

          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 55
             years, inclusive.

          -  Screening body mass index (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg

          -  Female subjects of childbearing potential must agree to use two effective methods of
             contraception from the date of Screening until 90 days after the last dose of EDP 938.

        Exclusion Criteria:

          -  Clinically relevant evidence or history of illness or disease.

          -  For Part 3 subjects, the following cardiovascular abnormalities:

               -  QRS duration &gt;110 ms

               -  Incomplete right bundle branch block or any complete bundle branch block

               -  Heart rate &lt;40 or &gt;90 beats per minute (per vital sign capture while rested)

               -  History of unexplained syncope, structural heart disease, or clinically
                  significant arrhythmias

               -  Personal or family history of long QT syndrome (genetically proven or suggested
                  by sudden death of a close relative due to cardiac causes at a young age) or
                  Brugada syndrome

               -  PR interval &gt;220 ms or any 2nd or 3rd degree AV block

               -  Ventricular pre-excitation

          -  Pregnant or nursing females.

          -  History of febrile illness within 7 days prior to the first dose of study drug or
             subjects with evidence of active infection.

          -  A positive urine drug screen at Screening or Day -1.

          -  Current tobacco smokers or use of tobacco within 3 months prior to Screening.

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).

          -  History of regular alcohol consumption.

          -  Participation in a clinical trial within 30 days prior to the first dose of study
             drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates, Inc.,</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Quinidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

